1-1-2023

Center for Biomedical Research at the Population Council

Population Council

Follow this and additional works at: https://knowledgecommons.popcouncil.org/series_newsletters_factsheets

How does access to this work benefit you? Click here to let us know!

Recommended Citation

This Fact Sheet is brought to you for free and open access by the Population Council.
Center for Biomedical Research at the Population Council

We are a global product development partnership committed to improving public health. We develop and ensure access to new and affordable products that promote sexual and reproductive health, rights, and choices for people in low- and middle-income countries.

The Center for Biomedical Research (CBR) addresses critical questions in sexual and reproductive health and develops innovative products that protect the health and well-being of millions of people worldwide.

CBR is located at Rockefeller University in New York City and leverages global partnerships with industry and academia, as well as synergistic collaborations with the Population Council’s international offices and affiliates and an expansive social and behavioral research program.

In 2022, the Council acquired the monthly dapivirine vaginal ring and other HIV prevention technologies from the International Partnership for Microbicides. The acquisition expands CBR’s product portfolio, solidifying our position as the leading innovator of high quality sexual and reproductive health (SRH) products that enhance choice for individuals in the global market.

CBR offers:

- The most robust product pipeline in sexual and reproductive health of any organization globally, with products at every stage of development for contraception, HIV, and multipurpose use.
- Unparalleled professional expertise in product formulation development, pre-clinical development, good manufacturing practices (GMP) manufacturing, clinical development, regulatory affairs, and product introduction.
- Extensive networks and partnerships are utilized throughout the product development and market introduction processes. This includes partnerships with academia, research and clinical trial networks, policymakers, the pharmaceutical industry, manufacturers, product distributors, and implementers. All of which help to ensure our products are introduced and accessible worldwide.
- Efficient and effective management and operations across research portfolios.

Our Vision

- Addressing unmet needs
- Expanding options for multipurpose prevention
- Offering a different/better side effect profile
- Developing and making available products that enhance safety and choice
- Enabling self-care

ENSURING SEXUAL & REPRODUCTIVE HEALTH, RIGHTS & CHOICES

Partner with us. Contact: Anita Garg, Senior Director, Strategy and Commercial Relations, agarg@popcouncil.org
## Approved SRH products developed and/or brought to market

<table>
<thead>
<tr>
<th>Product</th>
<th>Year Approved</th>
<th>Label Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paragard® Copper T 380A IUD</td>
<td>1984</td>
<td>10 years</td>
</tr>
<tr>
<td>Norplant® 6-rod Implant</td>
<td>1991</td>
<td>5 years</td>
</tr>
<tr>
<td>Jadelle® 2-rod Implant</td>
<td>1996</td>
<td>5 years</td>
</tr>
<tr>
<td>Progering® Vaginal Ring</td>
<td>1998</td>
<td>Multiple approvals 3 months</td>
</tr>
<tr>
<td>Mifeprax® Early Option Pill</td>
<td>2000</td>
<td>N/A Label duration</td>
</tr>
<tr>
<td>Mirena® Levonorgestrel IUS</td>
<td>2000</td>
<td>8 years</td>
</tr>
<tr>
<td>Annovera® Vaginal System</td>
<td>2018</td>
<td>12 months</td>
</tr>
<tr>
<td>Dapivirine® Vaginal Ring</td>
<td>2020</td>
<td>EMA positive opinion 1 month</td>
</tr>
</tbody>
</table>

## Our Impact

170 million women
Estimated to be currently using a Council-developed contraceptive product

10
Biomedical product approvals

20
US patents and FDA applications since 2009

24
Clinical trials initiated since 2010

5
Laboratories based at Rockefeller University

107
Research fellows, representing 29 countries, between 2010–2020

28
Peer-reviewed publications in high-impact journals in 2021

## Products in the Pipeline

### Contraception (F)

- Nestorone® and Estradiol Vaginal Ring
  - Pregnancy prevention

- Nestorone® + Testosterone Gel (NES/T Gel)
  - Male contraception

- Dapivirine Vaginal Ring (3-month DPV)
  - HIV prevention

### Contraception (M)

- Dapivirine Vaginal Ring with Levonorgestrel (DPV-LNG)
  - Pregnancy and HIV prevention

### HIV

- Dual Prevention Pill
  - Pregnancy and HIV prevention

- Etonogestrel, Ethinyl Estradiol, & Q-Griffithsin (EEQ IVR)
  - Pregnancy and HIV prevention

- Griffithsin FDI
  - HIV, HSV-2, and HPV prevention

- Nonhormonal Contraceptive & Q-Griffithsin MPT FDI
  - Pregnancy, HIV, STIs, and bacterial vaginosis prevention

- Non-hormonal IVR
  - Pregnancy, HIV, STIs, and BV prevention

### MPT

- 2nd-Generation Annovera®
  - Pregnancy prevention

- Nestorone® Vaginal Ring
  - Postpartum

- Weekly Mifepristone Pill
  - Pregnancy prevention

### Other

- 2nd Generation
  - Remyelination therapy

---

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Preclinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ring</td>
<td>Gel</td>
</tr>
<tr>
<td>Fast-dissolving insert</td>
<td>Injectable</td>
</tr>
<tr>
<td>Microneedle</td>
<td>Tablet</td>
</tr>
</tbody>
</table>